Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 1998

View Archived Issues

Astra: interim report January-September 1998

La Jolla Pharmaceutical: Q3 1998 highlights

Isis Pharmaceuticals: Q3 1998 highlights

Synaptic: Q3 1998 highlights

Pharmacia & Upjohn's reboxetine now available in Spain

Phase II data demonstrate efficacy of Avant's rotavirus vaccine

Cytogen and Berlex finalize supply agreement with DuPont for Quadramet

Novopharm Biotech completes patient enrollment for phase I study of NOVOMAb-G2

Two new antiplatelet agents marketed in Germany

Supratek, RPR Gencell work together to improve delivery of cardiovascular gene therapy

New raloxifene analogue is an even more potent and effective SERM than the parent compound

MK-0869 effective and well tolerated in patients with major depressive disorder

Sch-50971: a novel histamine H3 agonist with antimigraine and sedative effects in preclinical models

Osteoclast differentiation inhibitors for arthritis under study at Sumitomo

Ajinomoto identifies mechanism of anti-HSV and anti-VZV actions of A-5021

New MRI contrast agents with favorable neurotoxicity profile developed at Bracco

Bayer claims broad-spectrum oxazolidinones

Antiinflammatory tetrazoles in development at Ono

Merck & Co. presents potent and selective sst2 receptor agonists

New MMP inhibitor from Roche Bioscience limits arterial enlargement in rat model of AVF

Major clinical trials demonstrate efficacy of Rebetron in chronic HCV infection

Dual 5alpha-reductase inhibitors and alpha1-blocking agents prepared at Zeria

Swedish launch announced for PDE5 inhibitor Viagra

Thalidomide analogue CC-3052 is more active, less toxic than parent drug

Merck & Co. investigates sulfonamides as beta3-agonists with therapeutic potential in obesity

Adenosine + thrombolytics further reduces infarct size in acute MI; phase III trials in preparation

Diovan reduces left ventricular hypertrophy in hypertensive patients